Abstract
The substantia nigra and locus coeruleus are among the first brain regions to degenerate in Parkinson’s disease. This has important implications for early cognitive deficits as these nuclei are sources of ascending neuromodulators (i.e., dopamine and noradrenaline) that support various cognitive functions like learning, memory, and executive function. However, because most studies of the relationship between patterns of degeneration and cognition have either studied these neuromodulator systems in isolation or studied specific cognitive domains in isolation, it is unknown if degeneration in the substantia nigra and degeneration in the locus coeruleus independently and selectively contribute to different cognitive deficits in Parkinson’s disease.
To address this gap, we tested people with Parkinson’s disease and older adults on tasks of positive reinforcement learning, attention/working memory, executive function, and memory to measure performance in domains of cognition specifically thought to be related to dopaminergic and noradrenergic function. Participants also underwent neuromelanin-sensitive magnetic resonance imaging which provides a measure of degeneration of dopamine neurons in the substantia nigra and of noradrenergic neurons in the locus coeruleus. Brain-behaviour relationships were evaluated by separate linear regressions predicting cognitive performance in each domain from substantia nigra and locus coeruleus neuromelanin signal intensities controlling for age, sex, and education.
As expected, Parkinson’s disease patients had significantly slower learning from positive feedback and lower performance on tests of attention/working memory, executive function, and memory than controls. Parkinson’s patients also had lower neuromelanin signal intensity in the substantia nigra and locus coeruleus. Examining brain-behaviour relationships, we found that reduced neuromelanin signal in the substantia nigra in Parkinson’s disease patients was independently associated with impaired positive reinforcement learning, controlling for changes in the locus coeruleus, but was not associated with other domains of cognition. In contrast, reduced neuromelanin signal in the locus coeruleus was independently associated with impairments in attention/working memory and executive function, controlling for changes in the substantia nigra, but not with reinforcement learning performance. These results show that substantia nigra degeneration and locus coeruleus degeneration independently and selectively contribute to cognitive deficits and therefore suggests that individual differences in the degree of neurodegeneration in these nuclei could explain the significant heterogeneity that exists in the cognitive and behavioural manifestations of Parkinson’s disease. These findings also highlight the potential value of leveraging known brain-behaviour relationships to develop performance-based measures of cognition that reflect underlying patterns of neurodegeneration.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by funding from the Canadian Institutes of Health Research (MS), Fonds de Recherche Quebec - Sante (MS), Healthy Brains for Healthy Lives (SS), and Parkinson Canada (SS). JFG holds a Canada Research Chair in Cognitive Decline in Pathological Aging.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The McGill University Health Centre Research Ethics Board gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
De-identified participant data is available upon request.
